I don’t like the odds of success for this program for the reason mentioned in #msg-105048954 as well as my skepticism that Betrixaban is genuinely differentiated from the FXa inhibitors that failed in the indication being studied (VTE prevention in immobilized patients).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.